microdosing glp 1 for hashimoto's GLP-1 Microdosing" GLP-1: case studies and

A 26-week randomized trial showed that semaglutide at just 0.1 mg weekly still lowered A1c by about 1.4%, confirming that even microdoses can drive meaningful metabolic improvements

But the gap between those results, the side effect profiles, the costs, and the long-term sustainability of each approach has grown so wide that choosing the wrong one for your situation could mean years of frustration

In studies with rats and mice, Saxenda and medicines that work like Saxenda caused thyroid tumors, including thyroid cancer

Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors

Stephanie Widmer, a board-certified physician in emergency medicine, toxicology, and addiction medicine